Editas Medicine Inc reports results for the quarter ended in September - Earnings Summary

Editas Medicine

03/11/2023 13:31

* Editas Medicine Inc  EDIT.OQ  reported a quarterly
adjusted loss
of 55 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -81 cents.  The mean expectation of
seventeen analysts for the quarter was for a loss of 57 cents
per share. Wall Street expected results to range from -83 cents
to -45 cents per share.
    * Revenue rose 12,604.8% to $5.34 million from a year ago;
analysts expected $3.42 million. 
    * Editas Medicine Inc's reported EPS for the quarter was a
loss
of 55 cents​.
    * The company reported a quarterly loss of $45.02 million.
    * Editas Medicine Inc shares had fallen by 9.9% this
quarter and
lost 20.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.7%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 9
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Editas Medicine
Inc is $12.00 
This summary was machine generated from LSEG data November 3 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.57          -0.55          Beat
 Jun. 30 2023      -0.76          -0.56          Beat
 Mar. 31 2023      -0.78          -0.71          Beat
 Dec. 31 2022      -0.80          -0.88          Missed